# P. Kelly Marcom

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/p-kelly-marcom/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,397 |
| Field | Breast Cancer Treatment Studies |
| h-index | 57 |
| i10-index | 99 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5005726073 |
| ORCID iD | https://orcid.org/0000-0001-5302-6368 |
| Works | 191 |

## Researcher papers

- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-capecitabine-compared-with-bevacizumab-plus/)
- [Whole-genome analysis informs breast cancer response to aromatase inhibition](https://scholariq.org/papers/whole-genome-analysis-informs-breast-cancer-response-to-aromatase-inhibition/)
- [Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer](https://scholariq.org/papers/adjuvant-paclitaxel-and-trastuzumab-for-node-negative-her2-positive-breast/)
- [Genetic/Familial High-Risk Assessment: Breast and Ovarian](https://scholariq.org/papers/genetic-familial-high-risk-assessment-breast-and-ovarian/)
- [Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas](https://scholariq.org/papers/phase-i-safety-pharmacokinetics-and-clinical-activity-study-of-lapatinib/)
- [Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031](https://scholariq.org/papers/randomized-phase-ii-neoadjuvant-comparison-between-letrozole-anastrozole-and/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.